Boehringer Ingelheim Animal Health sees freshly mixed swine vaccines as its way forward

Boehringer Ingelheim Animal Health sees freshly mixed swine vaccines as its way forward

• Boehringer Ingelheim's research program on swine vaccines against PCV2/M.hyo revealed that the highest protection was observed for its vaccines when freshly mixed.
• A ready-to-use (RTU) design does not meet its standards for efficacy and safety.
• Boehringer Ingelheim continues to invest in the FLEX concept of freshly mixed vaccines.
Ingelheim, Germany, 1 September 2014 - Boehringer Ingelheim Animal Health, a market-leading manufacturer of swine vaccines, has decided to remain focused on freshly mixed Porcine Circovirus type 2 (PCV2)/Mycoplasma hyopneumoniae (M.hyo) vaccines and not follow the development of a PCV2/M.hyo ready-to-use (RTU)*1 vaccine combination. As a consequence, the company has discontinued its PCV2/M.hyo RTU research program.

Although initial data was promising, it became evident over time that in this case, the RTU design does not meet the high standards of efficacy and safety for which Boehringer Ingelheim's FLEXcombo® platform*2 is known. In essence, Boehringer Ingelheim´s PCV2/M.hyo research program revealed that the highest protection against both pathogens was observed for its vaccines when freshly mixed and applied in accordance with manufacturer recommendations.

The FLEXcombo® platform of mixable vaccines protects pigs against PCV2 and M.hyo with a single dose. In 2013, Boehringer Ingelheim introduced the MycoFLEX® headspace bottle, a simple and practical way to mix the two pig vaccines Ingelvac CircoFLEX® and Ingelvac MycoFLEX® for their simultaneous application. The same trusted concept is used for 3FLEX®, the mix of Ingelvac CircoFLEX®, Ingelvac MycoFLEX® and Ingelvac PRRS MLV® which is presently licensed in North America and several Asian countries.

Ingelvac CircoFLEX® is established globally as market leader for PCV2-vaccination*3 while Ingelvac MycoFLEX® is the market leader in a number of key swine markets*4. Boehringer Ingelheim is dedicated to continue its research efforts on these core antigens.
Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.
*1 In a ready-to-use (RTU) design, PCV2 (Porcine Circovirus type 2) and M.hyo (Mycoplasma hyopneumoniae) vaccines are pre-manufactured and stored in one bottle for later use.
*2 The FLEXcombo vaccine platform allows an easy mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® immediately before vaccination.
*3 Local and international market research data 2010, 2011, 2012, 2013, Q1-Q2 2014.
*4 Ingelvac MycoFLEX® market leadership includes markets like USA, Germany, The Netherlands, Italy, Poland, South Korea, Thailand and Taiwan and is based on 2013 local and international market research data (data on file).

Media contact
Matthias Kagerbauer
Boehringer Ingelheim

Matthias Kagerbauer
Binger Strasse 173
55216 Ingelheim am Rhein
Phone +49/6132/77 2356
Fax +49/6132/77 6601